Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. watchdog bans ads for weight-loss shake

This article was originally published in The Tan Sheet

Executive Summary

The U.K. body regulating advertisements bans the broadcast of commercials for Optislim weight-loss shakes. The ad shows a woman dressed for exercise and stretching, but instead of working out she drinks Optislim. A voice-over says, "Shake fat fast with Optislim three-second work out. Your complete weight-loss solution." Six viewers challenged the ad, saying it implied the product would have the same benefit as exercise. The Advertising Standards Agency says a text disclaimer stating, "when used as part of a calorie-controlled diet and healthy lifestyle," was insufficient to remove the implication that the product could replace exercise as part of a healthy lifestyle. The product maker said millions of people saw the ad and few complained, evidence that people were not misled. It added that the advertisement implied the woman got ready for exercise but realized she did not have time, so she drank an Optislim instead. The Federal Trade Commission previously filed orders against U.S. advertisements that claim products can help consumers lose weight without exercising (1"The Tan Sheet" Jan. 24, 2005)

You may also be interested in...



Weight-Loss Product Manufacturers Receive FTC Rebuke

A Federal Trade Commission settlement with the makers of Exercise in a Bottle and Fat Trapper barring the firms from marketing weight-loss products in the future is an example of the agency's willingness to deliver severe punishments against repeat offenders

Biocon And Mylan's Fulphila And Insulin Plans On Track

Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

Pharma Has High Hopes Of Pilot On Simultaneous Advice From EU Countries

Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers. 

Topics

UsernamePublicRestriction

Register

PS104461

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel